ADMET prediction is the computational process of forecasting a molecule's pharmacokinetic and toxicity profile—its Absorption, Distribution, Metabolism, Excretion, and Toxicity—before synthesis. By applying machine learning models trained on experimental data, these predictions identify compounds likely to fail due to poor bioavailability, rapid clearance, or off-target toxicity, enabling early-stage attrition of unsuitable candidates.
Glossary
ADMET Prediction

What is ADMET Prediction?
The in silico forecasting of a compound's Absorption, Distribution, Metabolism, Excretion, and Toxicity properties, used early in drug discovery to filter out molecules with poor pharmacokinetic or safety profiles.
Modern ADMET models leverage graph neural networks and molecular fingerprints to learn structure-property relationships from curated databases. Key endpoints include Caco-2 permeability, cytochrome P450 inhibition, hERG cardiotoxicity, and plasma protein binding. Integrating these predictions into multi-parameter optimization workflows allows medicinal chemists to balance potency with drug-like properties, reducing costly late-stage clinical failures.
Core ADMET Endpoints
The in silico forecasting of a compound's Absorption, Distribution, Metabolism, Excretion, and Toxicity properties, used early in drug discovery to filter out molecules with poor pharmacokinetic or safety profiles.
Absorption & Permeability
Predicts a compound's ability to cross biological membranes, primarily the intestinal wall, to reach systemic circulation. Key models forecast Caco-2 permeability and PAMPA values. Lipinski's Rule of Five serves as a foundational filter, flagging molecules with poor absorption due to high molecular weight (>500 Da), excessive hydrogen bond donors (>5), or high logP (>5). Modern graph neural networks directly predict the fraction absorbed in humans from molecular structure.
Distribution & Volume
Models the reversible transfer of a drug from the bloodstream into tissues and organs. Critical predictions include volume of distribution (Vd) and plasma protein binding (PPB) . A high Vd indicates extensive tissue binding, while high PPB limits the free, pharmacologically active fraction. AI models trained on human pharmacokinetic data can now predict blood-brain barrier penetration, a crucial parameter for CNS-targeted therapeutics.
Metabolism & Clearance
Forecasts the enzymatic biotransformation of a compound, primarily by the cytochrome P450 (CYP) enzyme family in the liver. Models predict intrinsic clearance (CLint) and identify specific sites of metabolism (SOM) . A key liability is CYP3A4 inhibition, which can cause dangerous drug-drug interactions. Deep learning models classify compounds as substrates or inhibitors of major CYP isoforms to predict metabolic stability.
Excretion & Half-Life
Predicts the removal of a compound and its metabolites from the body, primarily via renal or biliary routes. This is tightly coupled with metabolism to determine half-life (t1/2) , the time required for plasma concentration to drop by 50%. A short half-life necessitates frequent dosing, while an excessively long half-life risks accumulation. Models integrate clearance and volume of distribution data to forecast this critical dosing interval parameter.
Toxicity & Safety Liabilities
The most critical endpoint, forecasting adverse effects. In silico models flag structural alerts for mutagenicity (Ames test) , cardiotoxicity (hERG channel block) , and hepatotoxicity (DILI) . Advanced deep learning models trained on toxicogenomics data can predict complex organ-level toxicities. Identifying Pan-Assay Interference Compounds (PAINS) is also crucial to avoid false leads that appear active due to non-specific reactivity.
Multi-Parameter Optimization (MPO)
The simultaneous balancing of all ADMET properties to find a compound with an optimal overall profile. A potent molecule with poor solubility or high toxicity is a dead end. MPO algorithms use desirability functions to score compounds against a target product profile, trading off conflicting properties. This computational triage ensures only high-quality, drug-like candidates advance to costly in vivo studies.
Enabling Efficiency, Speed & Accuracy
Intelligent Analysis, Decision & Execution
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Talk to Us
Search across company data
Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.
Useful when people spend too long searching or get different answers from different systems.

Automate internal workflows
Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.
Useful when repetitive work moves across multiple tools and teams.

Add AI to products and internal tools
Build assistants, guided actions, or decision support into the software your team or customers already use.
Useful when AI needs to be part of the product, not a separate tool.
Frequently Asked Questions
Clear, technically precise answers to the most common questions about in silico ADMET prediction, covering mechanisms, model types, data requirements, and practical application in drug discovery workflows.
ADMET prediction is the computational forecasting of a compound's Absorption, Distribution, Metabolism, Excretion, and Toxicity properties using machine learning and physics-based models. It works by training quantitative structure-property relationship (QSPR) models on curated experimental datasets, where molecular descriptors—ranging from simple physicochemical properties like logP and molecular weight to complex graph neural network embeddings—are mapped to pharmacokinetic endpoints. During inference, a novel molecule's structure is featurized and passed through the trained model to output a predicted value (e.g., Caco-2 permeability in cm/s) or a classification (e.g., hERG blocker/non-blocker). Modern implementations often use multitask deep neural networks that learn shared representations across multiple ADMET assays simultaneously, improving generalization through inductive transfer. The goal is to fail early and cheaply: filtering out molecules with poor pharmacokinetic or safety profiles before costly synthesis and in vivo testing.
Related Terms
Key computational and experimental concepts that intersect with the in silico prediction of pharmacokinetic and toxicity properties.
Quantitative Structure-Activity Relationship (QSAR)
A foundational computational modeling method that establishes a mathematical relationship between the structural features (descriptors) of a set of chemicals and their biological activity or ADMET property.
- Descriptors: Can be 1D (logP), 2D (fingerprints), or 3D (electrostatic fields).
- Regression vs. Classification: Models predict continuous values (e.g., IC50) or categorical labels (e.g., toxic/non-toxic).
- Applicability Domain: A critical concept defining the chemical space where a QSAR model makes reliable predictions; extrapolation outside this space is invalid.
Multi-Parameter Optimization (MPO)
A computational strategy for simultaneously balancing multiple, often conflicting, drug-like properties to identify compounds with an optimal overall profile for development.
- The Core Problem: Potency, solubility, metabolic stability, and permeability rarely co-optimize naturally.
- Pareto Optimization: Identifies a frontier of solutions where improving one property necessarily degrades another.
- Desirability Functions: Combines disparate property scales into a single composite score to rank compounds holistically.
Pan-Assay Interference Compounds (PAINS)
A class of chemical compounds that frequently appear as false-positive hits in high-throughput screening due to non-specific reactivity, aggregation, or assay interference rather than genuine target binding.
- Mechanisms: Include redox cycling, covalent protein modification, and colloidal aggregation.
- Substructural Alerts: Defined by specific chemical moieties (e.g., rhodanines, phenolic Mannich bases) that are promiscuous hitters.
- Impact on ADMET: PAINS filters are a critical early triage step to prevent toxicophores and reactive compounds from entering downstream ADMET assays.
Activity Cliff
A pair of structurally similar molecules with a large difference in biological activity or ADMET property, representing a critical source of information for understanding structure-activity relationships.
- Definition: Typically defined by a high Tanimoto similarity (>0.7) paired with a large potency difference (>100-fold).
- Value: Reveals the precise structural features that act as a switch for a property, guiding medicinal chemistry decisions.
- Matched Molecular Pair Analysis (MMPA): The systematic cheminformatics approach used to identify and analyze activity cliffs by examining pairs differing by a single structural transformation.
Hit-to-Lead Optimization
The phase in early drug discovery where confirmed hit molecules are chemically modified to improve their potency, selectivity, and preliminary ADMET properties, transforming them into lead compounds.
- Primary Goal: Mitigate metabolic soft spots, improve aqueous solubility, and reduce off-target toxicity while maintaining or enhancing on-target activity.
- Iterative Cycle: Involves rounds of design, synthesis, and in vitro ADMET profiling (microsomal stability, Caco-2 permeability, hERG binding).
- In Silico Role: ADMET prediction models prioritize which analogs to synthesize, drastically reducing the number of compounds requiring experimental evaluation.
Free Energy Perturbation (FEP)
A rigorous, computationally intensive alchemical simulation method for calculating the relative binding free energy between two similar ligands, providing high-accuracy predictions for lead optimization.
- Mechanism: Computes the free energy change by slowly mutating one ligand into another through a series of non-physical intermediate states.
- Accuracy: Can achieve chemical accuracy (<1 kcal/mol error) for relative binding affinity predictions.
- ADMET Context: While primarily used for potency, FEP is increasingly applied to predict relative solvation free energies and membrane partitioning, key components of absorption and distribution.

About the author
Prasad Kumkar
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
Partnered with leading AI, data, and software stack.
How We Work
Custom AI workflows for your Business
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
01
Review the use case
We understand the task, the users, and where AI can actually help.
Read more02
Pick the right approach
We define what needs search, automation, or product integration.
Read more03
Build the first useful version
We implement the part that proves the value first.
Read more04
Improve from there
We add the checks and visibility needed to keep it useful.
Read moreThe first call is a practical review of your use case and the right next step.
Talk to Us